ADC Therapeutics announces results from LOTIS-5 Phase 3 confirmatory clinical trial
ADC Therapeutics announces results from LOTIS-5 Phase 3 confirmatory clinical trial of ZYNLONTA in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma.
Please find a link to our partner’s press release on the LOTIS-5 results.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Here we present our most recent press releases, stories, news articles, and images.
Find out more about our business and financial performance.
Every day, we work actively to find better ways to understand and meet patient needs.
- About
- Therapeutic areas
- Medicines
- Sustainability
- News & Stories
- Investors
- Careers
- English
- Swedish